Background: Inflammation and fibrosis are typical symptoms of non-alcoholic steatohepatitis (NASH), which is one of the most common chronic liver diseases. The cGAS-STING signaling pathway has been implicated in the progression of NASH, and targeting this pathway may represent a new therapeutic strategy. Licorice is a widely used herb with anti-inflammatory and liver-protective properties. In this study, we assessed the effect of licorice extract on the cGAS-STING pathway. Methods: Bone marrow-derived macrophages (BMDMs) were treated with licorice extract and then stimulated with HT-DNA, 2'3'-cGAMP, or other agonists to activate the cGAS-STING pathway. Quantitative real-time PCR and western blot were conducted to analyze whether licorice extract could affect the cGAS-STING pathway. Methionine and choline-deficient diet (MCD) was used to induce NASH in mice, which were treated with licorice extract (500Â mg/kg) by gavage and/or c-176 (15Â mg/kg) by intraperitoneal injection every 2Â days. After 6Â weeks of treatment, histological analysis of liver tissue was performed, along with measurements of plasma biochemical parameters. Results: Licorice extract inhibits cGAS-STING pathway activation. Mechanistically, it might function by inhibiting the oligomerization of STING. Treatment with licorice extract reduced inflammation and fibrosis in MCD diet-induced NASH mice models. Furthermore, we found that the therapeutic effect of combination treatment with licorice extract and C-176 (STING inhibitor) on the pathology and fibrosis of MCD diet-induced NASH models was similar to that of licorice extract or C-176 administered alone. Conclusion: Licorice extract can inhibit the cGAS-STING pathway and improve hepatic inflammation and fibrosis in NASH mice models. It strongly suggests that licorice extract may be a candidate therapeutic for NASH.
Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis.
甘草提取物抑制 cGAS-STING 通路,可预防非酒精性脂肪性肝炎
阅读:6
作者:Luo Wei, Xu Guang, Song Zheng, Mu Wenqing, Wen Jincai, Hui Siwen, Zhao Jia, Zhan Xiaoyan, Bai Zhaofang, Xiao Xiaohe
| 期刊: | Frontiers in Pharmacology | 影响因子: | 4.800 |
| 时间: | 2023 | 起止号: | 2023 Apr 4; 14:1160445 |
| doi: | 10.3389/fphar.2023.1160445 | 研究方向: | 炎症/感染 |
| 疾病类型: | 肝炎 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
